- cafead Dec 17, 2021 at 11:02: AM
via His second day on the job as Inozyme Pharma’s director of investor relations, Stefan Riley’s CEO came up to him and said, “Stefan, I hate our website.”
“That sounded like a call to action,” Riley said. So he set out to commission a soup to nuts rebrand for the rare disease biopharmaceutical company, starting with that website.
article source
“That sounded like a call to action,” Riley said. So he set out to commission a soup to nuts rebrand for the rare disease biopharmaceutical company, starting with that website.
article source